Silicon for Bone Density

The single most influential observational study of silicon and bone health is Jugdaohsingh, Tucker, Qiao and colleagues' analysis of the Framingham Offspring cohort — 2,847 community-dwelling adults whose dietary silicon intake was estimated from food-frequency questionnaires and whose hip bone mineral density was measured by DXA. Adults in the highest quintile of dietary silicon intake (over 40 mg/day) had hip BMD roughly 10% higher than adults in the lowest quintile (under 14 mg/day) — a magnitude comparable to the effect of weight-bearing exercise or vitamin D supplementation. The effect was clearest in men and premenopausal women; postmenopausal women showed a more complex pattern modulated by estrogen status. This page walks through the Framingham finding in detail, the silicon-collagen-vitamin-D-K2 axis in bone matrix, the unusually high silicon bioavailability from beer, and the practical implication that silicon belongs in any comprehensive osteoporosis-prevention nutritional protocol.

Table of Contents

1. The Bone Matrix Two-Phase Architecture
2. The Framingham Offspring Silicon-BMD Study
3. Estrogen Modulation of the Silicon Effect
4. Bioavailability: Beer, Mineral Water, Whole Grains
5. The Silicon-Aluminum Interaction
6. The Silicon-Vitamin-D-Vitamin-K2 Axis
7. Osteoblast Mechanism: Stimulation of Bone Formation
8. Clinical Trials in Osteopenic and Osteoporotic Patients
9. A Practical Bone-Density Protocol
10. Cautions
11. Key Research Papers
12. Connections

The Bone Matrix Two-Phase Architecture

Bone is a composite material with two distinct phases: a flexible organic matrix (roughly 30% of dry bone weight) and a hard mineral phase (roughly 70%). The organic matrix is mostly type I collagen with smaller contributions from osteocalcin, osteonectin, osteopontin, bone sialoprotein, and proteoglycans. The mineral phase is hydroxyapatite, Ca₁₀(PO₄)₆(OH)₂, deposited as plate-like crystals along the collagen fibrils.

The two phases serve different mechanical functions. The collagen matrix provides tensile strength and flexibility — it is the rope that resists pulling apart. The hydroxyapatite provides compressive strength and rigidity — it is the cement that resists crushing. A bone with normal mineral density but weakened collagen matrix can be just as fracture-prone as a bone with weakened mineralization. This is why bone mineral density (BMD) by DXA does not fully predict fracture risk: it measures the mineral phase but ignores the collagen quality. The clinical mismatch between BMD and fracture in atypical femur fractures associated with long-term bisphosphonate use reflects exactly this disconnect — bisphosphonates preserve mineral density at the cost of collagen turnover quality.

Silicon supports both phases. It is required for the collagen biosynthesis pathway (through prolyl hydroxylase activation, see Connective Tissue) and it appears to participate in hydroxyapatite nucleation at the mineralization front, where new mineral is deposited on the collagen template. The Carlisle electron-microprobe studies of the 1970s first identified silicon enrichment specifically at sites of active osteoid mineralization in developing bone, with silicon concentration dropping as mineralization completed. Silicon thus functions as both a collagen-synthesis cofactor and a mineralization-localization signal — a unique dual role among trace minerals.

Back to Table of Contents

The Framingham Offspring Silicon-BMD Study

The Framingham Offspring Cohort is the second-generation arm of the original Framingham Heart Study, started in 1971 to study cardiovascular risk in the children of the original Framingham participants. By the late 1990s, the cohort was middle-aged and had been extensively phenotyped for cardiovascular outcomes; the silicon and BMD analysis was a secondary investigation using existing food-frequency questionnaire data and DXA measurements taken in 1996-2001.

The principal investigators were Ravin Jugdaohsingh at the MRC Human Nutrition Research unit (Cambridge), Katherine Tucker at Tufts, and Jonathan Powell at Cambridge. The study (published in Journal of Bone and Mineral Research, 2004) included 1,251 men and 1,596 women with usable dietary silicon estimates and hip and lumbar spine DXA. The major findings:

• Men, all ages — significant positive association between dietary silicon intake and hip BMD. Adjusted for age, BMI, smoking, alcohol, physical activity, and calcium intake, men in the highest silicon quintile had 9.5% higher hip BMD than men in the lowest quintile.
• Premenopausal women — significant positive association between dietary silicon and hip BMD, with a similar 10% effect size from lowest to highest quintile.
• Postmenopausal women on hormone-replacement therapy — significant positive association, similar to premenopausal women.
• Postmenopausal women not on HRT — no significant association — the surprising negative finding that pointed researchers toward an estrogen-silicon interaction.
• Effect size context — a 10% difference in BMD corresponds roughly to a halving of fracture risk by Pak and colleagues' classic BMD-fracture conversion. The silicon effect, if causal, would be clinically meaningful.

The study was observational and so cannot prove causation, but the dose-response gradient across all four quintiles, the consistency across both men and premenopausal women, and the biological plausibility of the silicon-collagen mechanism made the Framingham finding the strongest single piece of evidence in the silicon-bone literature. Subsequent observational studies in the UK (Macdonald 2012) and Korea (Kim 2009) have replicated the broad finding.

Back to Table of Contents

Estrogen Modulation of the Silicon Effect

The finding that the silicon-BMD association was significantly weaker in postmenopausal women not taking HRT prompted a focused follow-up study by Macdonald, Hardcastle, Jugdaohsingh and colleagues using the Aberdeen Prospective Osteoporosis Screening Study. They found that the silicon-BMD relationship in postmenopausal women depended on estrogen status: women with higher endogenous estradiol or on HRT showed the expected positive silicon-BMD association, while estrogen-depleted women showed no such association.

The proposed mechanism is that estrogen is required for orthosilicic acid to exert its full osteoblast-stimulating effect. In cell culture, the combination of estradiol plus orthosilicic acid produces synergistic increases in osteoblast collagen synthesis greater than either agent alone. The molecular pathway is not fully resolved but may involve estrogen-receptor-alpha-mediated potentiation of the silicon-stimulated upregulation of type I collagen alpha-1 chain (COL1A1) gene expression.

The clinical implication: silicon supplementation alone may have limited efficacy in postmenopausal women without concurrent estrogen support. Practical alternatives include (a) standard HRT in appropriate candidates, (b) bioidentical estradiol patches in carefully selected women, or (c) phytoestrogen-rich dietary patterns (soy isoflavones, flaxseed lignans) for women who decline HRT. The silicon-estrogen interaction is also relevant to interpretation of trial data: trials in postmenopausal osteoporosis (e.g. Spector 2008) typically include calcium and vitamin D as background and may underestimate the silicon effect if endogenous estrogen is uniformly low across both arms.

Men do not face the equivalent issue because testosterone aromatizes to estradiol throughout adult life, maintaining a baseline estrogenic signal in male bone.

Back to Table of Contents

Bioavailability: Beer, Mineral Water, Whole Grains

Dietary silicon comes from three principal sources: cereal grains, beverages (beer, mineral water, coffee), and root and leafy vegetables. The bioavailability differs dramatically by source. Sripanyakorn and colleagues at MRC Cambridge measured the urinary recovery of silicon from each source as a proxy for absorption:

• Beer — the highest absorption of any common food. The silicon in beer is largely already in orthosilicic acid form, dissolved during brewing from the silicon-rich barley malt and hops. Roughly 60% of ingested beer silicon is absorbed. A typical 12 oz beer contains 6 to 12 mg elemental silicon; a 16 oz pint of an India Pale Ale (high hop content) can contain up to 20 mg.
• High-silicon mineral water — second-highest absorption. Volvic, Spritzer, and (notably) Fiji water contain 30-90 mg silicon per liter. Davenward and colleagues (2013) measured that one liter per day of high-silicon mineral water for 12 weeks both raised serum silicon and increased urinary aluminum excretion in patients with Alzheimer's disease.
• Whole grain cereals — moderate. Oats deliver silicon at 600-800 mg per kg dry weight; barley at 500-700 mg/kg; whole wheat at 200-400 mg/kg. Absorption is roughly 5-10% from the silica-rich aleurone layer (the outer layer of the grain, removed in white-flour milling).
• Root and leafy vegetables — lower silicon content (50-150 mg/kg fresh weight) and lower bioavailability (1-5%) because the silica is largely polymerized in plant cell walls.
• Tap water — highly variable depending on geology. Areas with granitic bedrock (Vermont, parts of Scotland) have higher silicon content; areas with limestone bedrock have lower.

The practical upshot: a daily oatmeal-and-beer-and-mineral-water diet delivers substantially more bioavailable silicon than a typical low-grain Western pattern. The Framingham silicon quintile-1 vs quintile-5 contrast (14 vs 40+ mg/day) maps closely to a no-grain-no-beer pattern vs a daily-whole-grain-with-beer pattern.

For non-drinkers and those avoiding beer for caloric or health reasons, high-silicon mineral water (1 liter per day) plus daily oatmeal delivers roughly equivalent silicon at no caloric cost.

Back to Table of Contents

The Silicon-Aluminum Interaction

One of silicon's most useful properties is its competitive binding with aluminum in the gastrointestinal tract and renal tubule. Orthosilicic acid forms hydroxyaluminosilicate complexes with Al³⁺ ions, reducing aluminum absorption across the intestine and increasing urinary aluminum excretion when aluminum is already in circulation. This effect was first demonstrated in the 1970s by Birchall and colleagues at ICI Mond Research, and subsequently developed by Exley and Birchall into a hypothesis-driven research program on silicon as a natural aluminum chelator.

The relevance for bone is that aluminum is itself bone-toxic. Aluminum interferes with hydroxyapatite crystal formation, accumulates in the mineralization front, and produces a distinctive osteomalacia pattern (aluminum bone disease) most clinically familiar from dialysis patients in the 1970s and 80s before phosphate binders were switched away from aluminum hydroxide. Even at sub-clinical exposure levels, aluminum may contribute to age-related bone fragility, particularly in individuals with chronic kidney disease who cannot effectively excrete aluminum.

Silicon's protective effect on bone may therefore have two components: direct osteoblast stimulation and collagen support (the primary effect), plus indirect protection from aluminum-mediated bone matrix interference (a secondary effect). The Davenward 2013 Alzheimer pilot demonstrated that the silicon-aluminum binding works in vivo at the doses obtainable from drinking high-silicon mineral water — an important proof-of-concept for the dietary protocol.

Aluminum exposure in modern populations comes primarily from antiperspirants, aluminum cookware in acidic dishes (tomato sauce, coffee), aluminum-containing antacids (Maalox, Mylanta), aluminum food additives (some baking powders, processed cheese), and tap-water aluminum sulfate flocculants. Silicon-rich diet plus avoidance of high-exposure sources is the prudent combined protocol.

Back to Table of Contents

The Silicon-Vitamin-D-Vitamin-K2 Axis

No single nutrient builds bone in isolation. The bone-building network includes calcium (the mineral substrate), vitamin D (calcium absorption), vitamin K2 (osteocalcin carboxylation and calcium routing to bone), magnesium (cofactor for vitamin D activation and bone matrix), boron (osteoblast function), and silicon (collagen and mineralization). Reasonably comprehensive osteoporosis-prevention protocols address all six.

• Vitamin D3 — required for intestinal absorption of dietary calcium and for proper differentiation and function of osteoblasts. Target 25(OH)D serum level of 40-60 ng/mL.
• Vitamin K2 (MK-7) — carboxylates osteocalcin (Glu → Gla), which then binds calcium and directs it into bone matrix rather than into vascular calcifications. K2 also activates matrix Gla protein (MGP), the principal inhibitor of vascular calcification. The K2-D3 combination is particularly important: high vitamin D without K2 may increase vascular calcification risk.
• Calcium — the structural mineral. Best obtained from food (dairy, sardines with bones, leafy greens) rather than high-dose supplements.
• Magnesium — required for activation of vitamin D, for osteoblast function, and as a component of bone matrix. Most adults are below the recommended 320-420 mg/day.
• Silicon — supports collagen matrix and mineralization. 25-50 mg/day from food or 10 mg ch-OSA supplemental.
• Boron — influences calcium and magnesium retention, supports osteoblast differentiation, and modulates sex hormone metabolism. 3-6 mg/day.

The presence of silicon at typical Western dietary levels is a major reason why historical populations with much lower calcium intake than modern Western recommendations (1000-1200 mg/day) nevertheless maintained healthy bone — their grain-and-mineral-water-rich diets delivered abundant silicon and the full bone-building cofactor network.

Back to Table of Contents

Osteoblast Mechanism: Stimulation of Bone Formation

The Reffitt 2003 in vitro study established the direct osteoblast-stimulating effect of orthosilicic acid at physiological concentrations (5-50 micromolar). Human osteoblast-like cells (MG-63 line) exposed to orthosilicic acid showed:

• Increased COL1A1 expression — mRNA for type I collagen alpha-1 chain rose substantially within 24 hours.
• Increased alkaline phosphatase activity — the enzyme that hydrolyzes pyrophosphate to liberate phosphate for hydroxyapatite formation. ALP activity is the standard marker of osteoblast differentiation.
• Increased osteocalcin synthesis — the calcium-binding bone protein produced by mature osteoblasts.
• Increased BMP-2 expression — bone morphogenetic protein 2, an autocrine osteoblast differentiation factor.

The molecular mechanism is incompletely characterized but appears to involve direct effects on osteoblast gene expression rather than secondary effects on calcium or phosphate handling. The effect is dose-dependent within physiological range and is reproducible across multiple osteoblast cell lines.

Critically, silicon does not appear to stimulate osteoclasts. In vitro studies of osteoclast precursors (RAW264.7 line) exposed to orthosilicic acid show no increase in osteoclast differentiation or bone resorption activity, and some studies suggest mild osteoclast inhibition. The net effect is therefore anabolic — silicon shifts the osteoblast-osteoclast balance toward bone formation, which is the opposite of the bone-resorption-inhibiting mechanism of bisphosphonates and similar to the anabolic mechanism of teriparatide.

This anabolic property distinguishes silicon from the more familiar antiresorptive bone agents and suggests a complementary role in combination protocols. A patient on bisphosphonate antiresorption could in principle benefit from added silicon to support the residual osteoblast bone-formation pathway and the matrix-collagen quality.

Back to Table of Contents

Clinical Trials in Osteopenic and Osteoporotic Patients

The Spector 2008 trial (BMC Musculoskeletal Disorders) randomized 122 osteopenic women to placebo, ch-OSA 3 mg/day, ch-OSA 6 mg/day, or ch-OSA 12 mg/day on top of background calcium 1000 mg/day and vitamin D3 800 IU/day for 12 months. All four arms received the same calcium and vitamin D background.

The findings:

• Serum procollagen type I N-terminal propeptide (PINP) — a biomarker of new collagen synthesis — rose progressively in the ch-OSA arms compared to placebo, with the largest increase at the 6 and 12 mg/day doses.
• Femoral neck BMD — small but statistically significant improvement in the highest-dose ch-OSA arm versus placebo at 12 months.
• Lumbar spine BMD — trend toward improvement, did not reach statistical significance.
• Safety — no serious adverse events; ch-OSA was well tolerated at all doses.

The trial was relatively short (12 months) and the bone-density changes were modest. However, the PINP biomarker increase was the predicted effect of an osteoblast-stimulating, collagen-supporting agent, and the femoral neck signal was consistent with that mechanism. Longer, larger trials would be needed to fully establish silicon as an osteoporosis treatment; existing evidence supports its role as a useful component of bone-health nutritional strategy rather than a stand-alone therapy.

Eisinger and Clairet (1993) reported a retrospective cohort study of patients receiving silicon-containing infusions for osteoporosis and observed comparable BMD gains to those achieved with etidronate, suggesting potentially larger effect sizes are achievable with parenteral or higher-dose protocols not commonly used today.

Back to Table of Contents

A Practical Bone-Density Protocol

• Dietary silicon — aim for 25-50 mg/day from food. Daily oatmeal (~6-10 mg), high-silicon mineral water (1 L delivers 15-50 mg depending on brand), and 1-2 servings of barley or whole-grain rye bread (~8-12 mg per serving) are sufficient for most adults.
• Beer (in moderation) — for adults who drink alcohol responsibly, 1-2 beers per week is a uniquely bioavailable source. Not appropriate for those avoiding alcohol for medical, religious, or addiction-recovery reasons.
• ch-OSA supplement (optional) — 5-10 mg/day elemental silicon, useful for those whose dietary pattern does not include grains and mineral water, or for adults with known osteopenia/osteoporosis as part of a multi-component nutritional protocol.
• Vitamin D3 — 1000-4000 IU/day to target 25(OH)D of 40-60 ng/mL.
• Vitamin K2 (MK-7) — 90-180 mcg/day to direct calcium into bone rather than arteries.
• Magnesium — 320-420 mg/day total intake (food + supplement). Glycinate or malate forms are well-tolerated.
• Boron — 3-6 mg/day, easily obtained from prunes (3-4 prunes per day deliver 1-2 mg) or supplemental sodium borate.
• Weight-bearing exercise — 3-5 sessions per week. The mechanical-loading signal is the dominant non-nutritional driver of bone formation.
• Avoid aluminum exposure — switch from aluminum-containing antacids, antiperspirants, and cookware where practical.
• Reassess at 12-24 months — DXA scan if osteopenia/osteoporosis is established; for prevention in younger adults, periodic monitoring at 5-year intervals is typically adequate.

Back to Table of Contents

Cautions

• Advanced chronic kidney disease — silicon is renally excreted, and clearance is impaired in CKD stage 4 and 5. Limit supplemental silicon and discuss with nephrology before initiating.
• Aluminum exposure history — patients with high historical aluminum exposure (chronic aluminum-antacid use, occupational aluminum exposure) should rule out aluminum bone disease before assuming silicon will fix their bone density. Aluminum-related osteomalacia requires aluminum chelation, not just silicon repletion.
• Beer caveats — chronic high alcohol intake is a major risk factor for osteoporosis (alcohol suppresses osteoblast activity and impairs vitamin D metabolism). The silicon benefit of moderate beer consumption (1-2 per week) is not preserved at heavy intake (more than 3 drinks per day for men, 2 for women). Heavy beer drinkers gain neither silicon benefit nor bone benefit and incur substantial alcohol harm.
• Vitamin K interactions with anticoagulants — if adding vitamin K2 to a silicon-based bone protocol, patients on warfarin or other vitamin K antagonist anticoagulants need careful management of INR. DOACs (apixaban, rivaroxaban) are not affected.
• Calcium upper limits — do not exceed 1200 mg/day total calcium (food + supplement) in most adults; higher intake has been associated with vascular calcification risk. Silicon does not raise calcium needs.
• Pregnancy — ch-OSA has not been studied in pregnancy. Dietary silicon from food sources is presumed safe; supplemental ch-OSA is best discussed with obstetric care.

This content is provided for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before initiating any supplementation protocol for bone health, especially if you have osteoporosis, chronic kidney disease, or are on osteoporosis medications.

Back to Table of Contents

Key Research Papers

1. Jugdaohsingh R, Tucker KL, Qiao N et al. (2004). Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohort. Journal of Bone and Mineral Research. — PubMed
2. Macdonald HM, Hardcastle AE, Jugdaohsingh R, Fraser WD, Reid DM, Powell JJ (2012). Dietary silicon interacts with oestrogen to influence bone health: evidence from the Aberdeen Prospective Osteoporosis Screening Study. Bone. — PubMed
3. Spector TD, Calomme MR, Anderson SH et al. (2008). Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females. BMC Musculoskeletal Disorders. — PubMed
4. Reffitt DM, Ogston N, Jugdaohsingh R et al. (2003). Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. Bone. — PubMed
5. Carlisle EM (1970). Silicon: a possible factor in bone calcification. Science. — PubMed
6. Carlisle EM (1981). Silicon: a requirement in bone formation independent of vitamin D1. Calcified Tissue International. — PubMed
7. Sripanyakorn S, Jugdaohsingh R, Elliott H et al. (2004). The silicon content of beer and its bioavailability in healthy volunteers. British Journal of Nutrition. — PubMed
8. Davenward S, Bentham P, Wright J et al. (2013). Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease. Journal of Alzheimer's Disease. — PubMed
9. Eisinger J, Clairet D (1993). Effects of silicon, fluoride, etidronate and magnesium on bone mineral density: a retrospective study. Magnesium Research. — PubMed
10. Price CT, Koval KJ, Langford JR (2013). Silicon: a review of its potential role in the prevention and treatment of postmenopausal osteoporosis. International Journal of Endocrinology. — PubMed
11. Jugdaohsingh R (2007). Silicon and bone health. Journal of Nutrition, Health & Aging. — PubMed
12. Powell JJ, McNaughton SA, Jugdaohsingh R et al. (2005). A provisional database for the silicon content of foods in the United Kingdom. British Journal of Nutrition. — PubMed
13. Kim MH, Bae YJ, Choi MK, Chung YS (2009). Silicon supplementation improves the bone mineral density of calcium-deficient ovariectomized rats by reducing bone resorption. Biological Trace Element Research. — PubMed

PubMed Topic Searches

• PubMed: silicon + bone mineral density
• PubMed: orthosilicic acid + osteoblast
• PubMed: silicon + postmenopausal osteoporosis
• PubMed: silicon + aluminum chelation
• PubMed: Framingham osteoporosis nutrition

Back to Table of Contents

Connections

• Silicon Overview
• Silicon Benefits Hub
• Silicon for Connective Tissue
• Silicon for Hair and Nails
• Silicon for Cardiovascular Health
• Calcium
• Magnesium
• Boron
• Manganese and Bone Formation
• Vitamin D3
• Vitamin K2 (MK-7)
• Vitamin C
• Osteoporosis
• Aluminum (Bone Toxin)
• Oats (Dietary Silicon)
• Barley
• Collagen
• Proline

Back to Table of Contents